ArticleClinical, cosmetic and investigational dermatology2026
IL-36 Receptor Antagonist Spesolimab for Generalized Pustular Psoriasis Combined with Palmoplantar Pustulosis: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We have entered the era of using biologics and small-molecule targeted drugs to treat diseases. Although there have been many reports on the use of the anti-interleukin-36 (IL-36) receptor antagonist spesolimab for the treatment of generalized pustular psoriasis (GPP) recently, the clinical application of spesolimab for the treatment of GPP combined with PPP (palmoplantar pustulosis) is rarely reported, and there is a lack of evidence on the safety and efficacy of the spesolimab.The clinical application of spesolimab for GPP combined with palmoplantar pustulosis (PPP) is rarely reported, and evidence on its safety and efficacy remains insufficient. We aimed to explore the use of spesolimab for GPP combined with PPP and observed significant efficacy without obvious side effects, thereby providing new ideas for the clinical treatment of GPP combined with PPP. Methods: We reported a case of GPP combined with PPP treated with spesolimab, which achieved significant therapeutic effects without significant side effects. Results: This case report shows that spesolimab has good clinical efficacy in treating GPP combined with PPP. In this case, the presence of PPP may have delayed the rapid and complete clearance of the skin lesions. Conclusion: Spesolimab provides a new treatment option for patients with GPP combined with PPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.